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ABSTRACT
AroundtabletodiscussthemeasurementofvitaminB-12(cobalamin)
status biomarkers in NHANES took place in July 2010. NHANES
stopped measuring vitamin B-12–related biomarkers after 2006.
The roundtable reviewed 3 biomarkers of vitamin B-12 status used
in past NHANES—serum vitamin B-12, methylmalonic acid (MMA),
and total homocysteine (tHcy)—and discussed the potential utility
of measuring holotranscobalamin (holoTC) for future NHANES.
Theroundtablefocusedonpublichealthconsiderationsandthequality
of the measurement procedures and reference methods and materials
that past NHANES used or that are available for future NHANES.
Roundtable members supported reinstating vitamin B-12 status mea-
sures in NHANES. They noted evolving concerns and uncertainties
regarding whether subclinical (mild, asymptomatic) vitamin B-12
deﬁciency is a public health concern. They identiﬁed the need for ev-
idencefromclinicaltrialstoaddresscausalrelationsbetweensubclin-
ical vitamin B-12 deﬁciency and adverse health outcomes as well as
appropriatecutoffsforinterpretingvitaminB-12–relatedbiomarkers.
Theyagreedthatproblemswithsensitivityandspeciﬁcityofindividual
biomarkersunderscoretheneedforincludingatleastonebiomarkerof
circulating vitamin B-12 (serum vitamin B-12 or holoTC) and one
functional biomarker (MMA or tHcy) in NHANES. The inclusion
of both serum vitamin B-12 and plasma MMA, which have been
associated with cognitive dysfunction and anemia in NHANES
andinotherpopulation-basedstudies,waspreferabletoprovideconti-
nuitywithpastNHANES.Reliablemeasurementproceduresareavail-
able, and National Institute of Standards and Technology reference
materials are available or in development for serum vitamin B-12 and
MMA. Am J Clin Nutr 2011;94(suppl):313S–21S.
INTRODUCTION
The NHANES are a valuable source of data on the nutritional
and health status of the US population. The surveys require
highly accurate measurement procedures to ensure that their
prevalence estimates are comparable with commonly used
cutoffs of nutrient adequacy and safety, and that trends in these
estimatesovertimeareattributabletorealchangesinnutritional
status.
Currently, NHANES does not measure serum vitamin B-12 or
any other vitamin B-12–related biomarkers. However, NHANES
II (1976–1980), the second half of NHANES III (1991–1994),
and NHANES 1999–2006 measured serum vitamin B-12 concen-
trations. Furthermore, NHANES III (1988–1994) and NHANES
1999–2004 measured methylmalonic acid (MMA) concentrations,
and NHANES III (1991–1994) and NHANES 1999–2006 mea-
sured total homocysteine (tHcy) concentrations.
The National Center for Health Statistics of the Centers for
Disease Control and Prevention and the Ofﬁce of Dietary Sup-
plementsoftheNationalInstitutesofHealthconvenedaroundtable
panel on July 15–16, 2010, in Rockville, MD, to review the mea-
surement of biomarkers of folate and vitamin B-12 status in
NHANES. In this article, we summarize the roundtable’s dis-
cussion, which focused on the following: 1) public health con-
siderations for including vitamin B-12–related biomarkers in
NHANES and 2) the quality of the vitamin B-12–related mea-
surement procedures and reference methods and materials that
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articles in this supplement issue summarize general background
information on biomarker measurement and use issues and the
roundtable’s review of folate status biomarkers (1–3). In an in-
troductory article, we describe how the individual articles in this
supplement ﬁt within the overall roundtable process (4). We also
describe the relevance of the roundtable review and dialogue to
clinical and research settings outside the NHANES context.
THE ROUNDTABLE
Theroundtablepanelconsistedof23expertsinfolateandvitamin
B-12 assessment, clinical laboratory science, and biostatistics and
10 scientists from US government agencies that generate or use
NHANES data and develop reference methods and materials for
these measures.
The roundtable reviewed 3 biomarkers of vitamin B-12 status
usedin NHANES:vitamin B-12,MMA, and tHcy.This article,in
comparisontothefolate-relatedbiomarkerssummary(3),includes
theroundtable’sdiscussionsoftHcybecausevitaminB-12statusis
thepredominantnutrientdeterminantofhightHcyconcentrations
among US population groups (5–7). The roundtable also consid-
ered holotranscobalamin’s (holoTC’s) possible utility as an in-
dicator of vitamin B-12 status for future NHANES (8, 9).
The roundtable reviewed vitamin B-12–related public health
and measurement quality issues in the context of the NHANES
mission and capabilities. The experts did not consider broader
research and clinical application issues for these biomarkers or
differences in themeasurementprocedures thatresearch, clinical,
and commercial laboratories use. The roundtable identiﬁed and
discussed the scientiﬁc issues involved in deciding whether to
includevitaminB-12–relatedbiomarkersinfutureNHANES.For
ease of use, we used the more common terminology of “vitamin
B-12” in place of the more precise terminology of “cobalamin”
(9). When we used serum vitamin B-12 data in this article, we
converted the values to pmol/L (1.0 pg/mL or ng/L = 0.7378
pmol/L). For plasma MMA, we converted the values to nmol/L
(1.0 ng/mL or lg/L = 8.468 nmol/L).
MONITORING OF VITAMIN B-12 STATUS IN NHANES
The roundtable focused on 2 key vitamin B-12–related mon-
itoring issues: 1) the public health need for assessing vitamin
B-12 status and 2) the usefulness of several biomarkers in con-
ducting these assessments. Ralph Carmel outlined key issues for
the roundtable to consider (9). Regan Bailey provided data on
vitamin B-12 status assessments for adults in NHANES.
Public health need for monitoring of vitamin B-12 status
The roundtable considered whether the primary purpose of
monitoringtheUSpopulation’svitaminB-12statusistodetermine
theprevalenceoftheuncommonandseriousclinicalvitaminB-12
deﬁciency characterized by megaloblastic anemia and/or neuro-
cognitivedysfunction;’94%ofthesecasesarisefrompernicious
anemia.Alternatively,theprimarypurposecouldbetomonitorthe
more common subclinical (mild, asymptomatic) vitamin B-12
deﬁciency, deﬁned by abnormal concentrations of vitamin B-12–
related biomarkers [also referred to as SCCD or subclinical co-
balamin deﬁciency (9)]. Approximately 1–2% of the elderly US
population has clinical vitamin B-12 deﬁciency, and ’10–20%
has subclinical deﬁciency (10).
BecauseNHANESisnotwellsuitedformonitoringraremedical
conditions such as pernicious anemia, the roundtable found the
question posed by Carmel as to whether monitoring the more
common subclinical deﬁciency has public health merit (9) to be
a helpful anchor point for their overall dialogue. The common
assumptionthatdetectingsubclinicaldeﬁciencyearlyisimportant
toenablepublichealthinterventionsthatpreventitsprogressionto
clinical deﬁciency lacks conﬁrmatory evidence (9). Subclinical
deﬁciencyoftenarisesfromdifferentcauses(eg,malabsorptionof
food-bound cobalamin or unidentiﬁed causes) than does clinical
deﬁciency(eg,absenceofintrinsicfactorduetoperniciousanemia)
(9,10).Moreover,limitedevidencesuggeststhatmanyindividuals
withsubclinicaldeﬁciency,evenwithouttreatment,spontaneously
regain normal vitamin B-12 status or experience no further de-
terioration after several years, raising questions about the public
health concerns with subclinical deﬁciency (9–11).
Subclinical vitamin B-12 deﬁciency per se may adversely
affect cognitive or neurologic function. Results from some, but
not all, observational studies show associations between vitamin
B-12 deﬁciency and cognitive impairment (12–17). The round-
table noted, however, that no clinical trials have conﬁrmed a
causal relation between subclinical vitamin B-12 deﬁciency and
adverse outcomes. Therefore, the roundtable agreed that the
public health implications of subclinical vitamin B-12 deﬁciency
areuncertain,althoughtheobservationalevidenceonadverseeffects
is of concern and warrants further evaluation.
Biomarkers of vitamin B-12 status
The roundtable considered the usefulness of available bio-
markersforassessingvitaminB-12statusinNHANES.Biomarker
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whether (and, if so, how) factors unrelated to vitamin B-12 status
affect these biomarkers. The roundtable also discussed whether
commonlyuseddeﬁciencycutoffsaremeaningfulfortheNHANES
sample (the general US population) and for the NHANES mea-
surement procedures.
Currently availablebiomarkers canbe categorizedas those that
directlymeasurethevitaminB-12inbloodandthosethatmeasure
metabolitesthataccumulatewithinadequateamountsofvitaminB-
12(8–10,18).SerumvitaminB-12andholoTCmeasurecirculating
vitaminB-12concentrations.Thesebiomarkersthereforereﬂectthe
broadvitaminB-12statusrangefromhighriskofseveredeﬁciency
to adequacy. MMA and tHcy, which are functional (metabolic)
measuresofvitaminB-12status,accumulatewhenconcentrations
of vitamin B-12 are inadequate; tHcy also accumulates with in-
adequate amounts of folate and, to a lesser degree, riboﬂavin and
vitamin B-6. These functional measures are useful for identifying
subclinicalvitaminB-12statusandreﬂectearlychangesinvitamin
B-12 status. Information from both types of biomarkers can yield
amoreaccurateassessmentofvitaminB-12statusthaninformation
from only one vitamin B-12 status category (9).
FactorsunrelatedtovitaminB-12statusaffectall4biomarkers
(8–10, 18–20). Impaired renal function alters MMA and tHcy and,
to a lesser extent, holoTC and serum vitamin B-12 concentrations.
Other factors, such as individual genetic variation, disease con-
ditions, prescription and other drug use, and pregnancy can also
affect the biomarkers. Measurement procedure errors and other
technological problems produce spuriously high or low biomarker
concentrations (9). These factors adversely affect the biomarkers’
sensitivity and speciﬁcity and result in false-positive or false-
negative classiﬁcations of vitamin B-12 deﬁciency.
These classiﬁcation errors are particularly important for sur-
veys such as NHANES that cannot conduct the follow-up di-
agnostic testing required for vitamin B-12 deﬁciency diagnosis
and treatment (9). For example, high MMA and tHcy concen-
trations occur across all serum vitamin B-12 concentrations,
although they are most prevalent in people with the lowest vi-
tamin B-12 concentrations (9). Clinical data show that ’2.5–
5.2% of patients with diagnosed vitamin B-12 deﬁciency have
serum vitamin B-12 concentrations above a commonly used cut-
off for low values (148 pmol/L), and an even higher proportion of
persons with abnormal MMA or tHcy concentrations have serum
vitamin B-12 concentrations .148 pmol/L (9). Approximately
20% of persons with low serum vitamin B-12 concentrations have
neither clinical nor metabolic signs of vitamin B-12 deﬁciency.
The roundtable agreed that because of problems with these bio-
markers’ sensitivity and speciﬁcity, measuring a circulating bio-
marker (vitamin B-12 or holoTC) and a functional biomarker
(MMA or tHcy) concurrently is preferable to measuring only
one biomarker in NHANES.
The roundtable also reviewed the relevance of common cutoffs
for the NHANES population. The vitamin B-12 cutoffs that sci-
entists and clinicians use generally are consistent with 2 or 3 SDs
from a reference range’s mean. A cutoff value consistent with 2
SDs is ’200 pmol/L, and a value of 148 pmol/L is consistent with
3 SDs (9, 18). A cutoff of 148 pmol/L misses 3–5% of patients
with clinical deﬁciency, whereas ’200 pmol/L identiﬁes all pa-
tients but produces more false-positive results. Systematic bias
and spurious results affected some measurement procedures used
in the past to derive reference ranges (9). The cutoff used affects
NHANES prevalence estimates. Using cutoffs similar to those
used in the published literature, Regan Bailey (personal commu-
nication, 2011) found a prevalence (least-squared percentage 6
S E )o f2 . 86 0.2% for serum vitamin B-12 concentrations ,148
pmol/L, 10.5 6 0.4% for concentrations ,198 pmol/L, and 25.6 6
0.6% at ,258 pmol/L in an NHANES sample of people aged
60 y with impaired but controlled renal function.
MMAcutoffsalsorangeconsiderably,from210to480nmol/L
(9). Researchers have based MMA cutoff values on an approxi-
mationoftheinﬂectionpointatwhichMMAconcentrationsstartto
increasewithdecreasingserumvitaminB-12concentrationsoron
a percentile of a population-based reference range, or on fully
cobalamin-replete subjects (12, 18, 21). The cutoff value used
affectsprevalenceestimates.InanNHANESsampleofadultsaged
60 y in whom impaired renal function was controlled, Regan
Bailey found that a cutoff .376 nmol/L resulted in a prevalence
of 2.4%, whereas a cutoff .271 nmol/L produced a prevalence
of 5.9% (RL Bailey, personal communication, 2011).
The roundtable discussed the urgent need to base cutoffs for
biomarker concentrations on adverse outcome occurrences. The
needforsuchcutoffsisparticularlycriticalforsubclinicalvitaminB-
12 deﬁciency, which is the predominant type of vitamin B-12 de-
ﬁciency in NHANES populations because it is asymptomatic and
research has not conﬁrmed a causal relation between subclinical
deﬁciencyandadversehealthoutcomes.Validationofcutoffvalues
requires clinical trials and accurate and reliable measurement pro-
cedures. Cross-sectional studies, such as NHANES, and other ob-
servationalstudiescannotvalidatecutoffs,althoughthesestudiescan
helpgenerate hypotheses and examine relationsbetweenvariables.
MEASURES OF VITAMIN B-12–RELATED BIOMARKERS
IN NHANES
The roundtable reviewed the quality and appropriateness of
NHANESprocedurestomeasurevitaminB-12–relatedbiomarkers.
Except for 2 special postsurvey projects at Tufts University that
used surplus sera to measure MMA and tHcy in the second phase
ofNHANESIII(1991–1994)(22,23),theDivisionofLaboratory
ScienceattheNationalCenterforEnvironmentalHealth(NCEH)
ofthe Centersfor Disease Controland Prevention measuredserum
vitamin B-12 and plasma MMA and tHcy in NHANES. Christine
Pfeiffer reviewed the NCEH laboratory procedures and results for
the roundtable.
Measurement of serum vitamin B-12 in NHANES
NHANES used the Bio-Rad Quantaphase II radioimmuno-
assay (RIA) kit for (Bio-Rad Laboratories, Hercules, CA) all
serum vitamin B-12 measures except for the 1976–80 survey,
which used the Quantaphase I kit (Table 1) (24–28). In 2007, the
manufacturer discontinued the Bio-Rad RIA. The loss of this assay
kit and the ﬁnding that serum vitamin B-12 concentrations col-
lected from NHANES III (1991–1994) to NHANES 2006 had
not changed appreciably (1) resulted in a decision to drop mea-
sures of vitamin B-12 status after NHANES 2006.
WiththeQuantaphaseIIkit,theNCEHobtainedlong-termCVs
(NHANES1999–2004)of3–6%forconcentrationsof’280–1200
pmol/L (29). Quality-control (QC) pools were stable and re-
producible across all surveys. For reference material 81/563 from
the National Institute for Biological Standards and Control
(NIBSC; http://www.nibsc.ac.uk/products/biological_reference_
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234 6 14 pmol (n = 27) from 1994 to 2006 compared with an
NIBSC-certiﬁedconcentration of 236pmol/ampule. Over several
years in the College of American Pathologists (http://www.cap.
org/apps/cap.portal) proﬁciency testing program, the NCEH re-
sults were ’20% higher than the College of American Patholo-
gists all-laboratory trimmed mean; the Bio-Rad RIA had no peer
group using this measurement procedure with which to directly
compare results.
Because the NCEH anticipated that NHANES might consider
reinstating vitamin B-12 measures at a later date, it evaluated the
Roche Elecsys 170 chemiluminescent measurement procedure
(Roche, Basel, Switzerland). The result was 373 pmol/ampule for
the NIBSC 03/178 reference material, with an assigned reference
value of 354 pmol/ampule. When the NCEH fortiﬁed a serum pool
with this reference material, complete recovery resulted (103%).
TheNCEHuseditsRocheE-170proceduretocharacterize3levels
ofNationalInstituteofStandardsandTechnology(NIST)standard
reference material (SRM) 3951 (30), which is under de-
velopment. The NISTwill use resultsfrom higher-order reference
measurement procedures to assign this SRM’s target values.
NCEH-measured mean (6SD) vitamin B-12 concentrations were
42.6 6 5.8 (CV: 13.7%), 114.4 6 6.0 (CV: 5.3%), and 283.1 6
7.3 pmol/L (CV: 2.6%) (n = 12) for this reference material. The
NCEH obtained within-day CVs (n = 10) of 0.9–2.1% for its low
and high (’175 and 825 pmol/L) QC pools. Between-day CVs
over 5 mo (n = 22) were 3.8–6.5% for 5 QC pools with concen-
trations of ’200–900 pmol/L. The manufacturer-speciﬁed limit of
detection for this serum vitamin B-12 measurement procedure
was 22 pmol/L.
Inacrossoverstudy(n=280),theNCEHreanalyzedNHANES
samples it had previously measured with the Bio-Rad Quanta-
phase II RIA by using the Roche E-170 measurement procedure
to determine the procedures’ comparability. The median was 390
pmol/LfortheBio-Radand438pmol/LfortheRocheprocedure,and
the Pearson correlation coefﬁcient was 0.98 over a range of ’45–
1100 pmol/L. A log transformation removed the distribution’s
skewness with a Deming regression ﬁt of log vitamin B-12Roche =
0.97 · log vitamin B-12Bio-Rad + 0.10 pmol/L and showed a small
but signiﬁcant constant and proportional bias (Figure 1A). The
Bland-Altman bias plot showed a mean relative bias of 10.7% for
the Roche procedure compared with the Bio-Rad procedure, with
95% limits of agreement from 25.6% to 27% (Figure 1B).
Measurement of plasma MMA in NHANES
The NCEH used gas chromatography/mass spectrometry (GC/
MS) to measure plasma MMA in NHANES (Table 2) (31–34),
resulting in long-term CVs (NHANES 1999–2004) of 3–8% for
low QC pools (’100–500 nmol/L), 2–4% for medium QC pools
(1000–2000 nmol/L), and 2.0–3.5% for high QC pools (’10,000
nmol/L). QC pools were stable and reproducible across all sur-
veys. As a participant in the Danish External Quality Assess-
ment program since 2000, the NCEH’s MMA results have
consistently been within the acceptance interval that the pro-
gram calculated from biological variation (621% of the pro-
gram mean). The NCEH’s results were, on average, 6% lower
than the program mean.
If NHANES reinstates MMA measures in future surveys, the
NCEH could use their GC/MS measurement procedure because
the NCEH has maintained proﬁciency in this procedure despite
its absence from recent NHANES. However, the NCEH is
considering using a liquid chromatography–mass spectrometry
(LC-MS/MS) procedure similar to the one that several labora-
tories haverecently used(35–37). The roundtable encouraged the
NCEH to use LC-MS/MS for future analyses.
Measurement of tHcy in NHANES
The measurement procedures, QC data, and survey compa-
rabilityoftHcyinNHANESaredescribedelsewhere(38–45)and
are summarized in Table 3. The NCEH observed long-term
(NHANES 1999–2004) CVs of 3–5% for multiple QC pools
covering a tHcy concentration range of ’6–27 lmol/L (45). QC
pools were stable and reproducible in all surveys. The NCEH
Abbott AxSym (Abbott Diagnostics, Abbott Park, IL) results
were within 10% of the NIST SRM 1955 certiﬁed values, 9%
higher for the low level (’4 lmol/L), 1% higher for the medium
level (’9 lmol/L), and 6% lower for the high level (’18 lmol/L).
As a participant in the Danish external quality assurance program
in 2000–2008, the NCEH consistently obtained tHcy results within
the program’s acceptance interval on the basis of biological vari-
ation (617% of the program mean). The NCEH’s results were, on
average, 0.2% higher than the program mean.
Possible measurement of holoTC in NHANES
Ebba Nexo (8) described several procedures for assessing
holoTC, including a new enzyme-linked immunosorbent assay
procedure on the Abbott AxSym analyzer platform. This pro-
cedure is easier to use than previous ones and can measure
holoTC directly without sample pretreatment (46). In a com-
parison study in Europe, all available methods gave similar values
(47). Enzyme-linked immunosorbent assay measurement had a 4–
5% imprecision rate and a 5–20 pmol/L method-dependent de-
tection limit.
NIST REFERENCE METHODS AND MATERIALS
Theroundtablereviewedthequalityandappropriatenessofthe
NIST reference methods and materials for use in NHANES to
achieve traceability of NHANES measurements to a higher-order
reference method and materials. Karen Phinney discussed the
development of reference methods and materials for vitamin
B-12, tHcy, and MMA at the NIST.
TABLE 1
Vitamin B-12 biomarker measurement in NHANES
1
Survey Measurement procedure Matrix Laboratory Population age
1974–1975 — — — —
1976–1980 Bio-Rad QP I Serum NCEH 6 mo–74 y, subset
1988–1991 — — — —
1991–1994 Bio-Rad QP II Serum NCEH 4y
1999–2000 Bio-Rad QP II Serum NCEH 3y
2001–2002 Bio-Rad QP II Serum NCEH 3y
2003–2004 Bio-Rad QP II Serum NCEH 1y
2005–2006 Bio-Rad QP II Serum NCEH 1y
2007–2008 — — — —
2009–2010 — — — —
1 QP, Quantaphase (Bio-Rad Laboratories, Hercules, CA); NCEH, Na-
tional Center for Environmental Health, Centers for Disease Control and
Prevention.
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Currently, the NIST has no SRM with certiﬁed values for vi-
tamin B-12 or MMA, although it provides information values for
vitamin B-12 using RIA in SRM 1955 (48). The NIST is de-
veloping SRM 3951 (30) for serum vitamin B-12 with target pools
of 74 pmol/L (100 pg/mL), 148 pmol/L (200 pg/mL), and 332
pmol/L (450 pg/mL). The 332-pmol/L pool is “normal” serum,
whereasthe2lowerpoolsareablendofnormalandserumstripped
of its naturally occurring vitamin B-12.
Unique challenges in developing a higher-order vitamin B-12
measurement procedure include the forms of vitamin B-12 to
measure. One challenge is whether converting all forms to cy-
anocobalamin and measuring this compound to determine total
serum vitamin B-12 best meets user needs. Also, do users need to
evaluate the different biologically relevant species? Another
challenge is the low concentrations that will be encountered in
some individuals with low vitamin B-12 status (’100 pmol/L or
less) of serum vitamin B-12. To account for potential analyte
losses during sample preparation, a stable-isotope–labeled in-
ternal standard should be used, but chemical synthesis of an
isotopically labeled form of vitamin B-12 is not currently fea-
sible. A labeled form of vitamin B-12 would be the ideal internal
standard because it should behave similarly to the unlabeled
endogenous form, including binding to the 2 circulating vitamin
B-12 binding proteins (haptocorrin and transcobolamin). Alter-
native options might be a labeled compound produced by bac-
teria or partial chemical synthesis incorporating isotopically
labeled precursor compounds.
The NIST has not found a good internal standard candidate
among other structurally related compounds. On the basis of
preliminary work using LC-MS/MS, the NIST has identiﬁed some
vitamin B-12 species that it could quantify. Remaining challenges
include obtaining the needed sensitivity, developing an appro-
priate quantitation mechanism, and obtaining sufﬁcient precision
to certify concentration values in the reference materials. The
roundtable suggested developing a valid LC-MS/MS method to
measure total cobalamin after converting all species to cyanoco-
balamin. Characterization of vitamin B-12 species is a long-term
goal, but a need exists now for an SRM for total cobalamin.
The NIST is currently developing MMA reference methods
and materials. Phinney reported that GC/MS and LC-MS/MS
procedures using derivatized or underivatized compounds work
well. The NIST is developing new reference materials for SRM
909(49)andﬁndsthatthesematerialsareappropriateforSRMuse
(MMA concentration of ’170 nmol/L). The NIST’s SRM 1950
(50) materials are also appropriate (MMA of ’300 nmol/L).
However, SRM 3591 (30), which is under development, is not
appropriate (MMA of ’35 nmol/L).
NIST methods and materials for tHcy
NIST SRM 1955 has certiﬁed values for mean (6expanded
uncertainty) tHcy concentrations of 3.98 6 0.18 lmol/L, 8.85 6
0.60 lmol/L, and 17.7 6 1.1 lmol/L (48, 51–53). Level 2 is a
naturally occurring serum material, level 1 is diluted, and level 3 is
fortiﬁed to achieve target concentrations. In a commutability study
with 20 fresh-frozen samples and a limited concentration range,
SRM 1955 was commutable across 14 commercial tHcy immuno-
and enzymatic assays (54). The Joint Committee for Traceability in
Laboratory Medicine database lists the NIST GC-MS and LC-MS/
MS methods as reference measurement procedures (55).
ROUNDTABLE DIALOGUE: VITAMIN B-12–RELATED
BIOMARKERS IN NHANES
The roundtable members were generally satisﬁed with the mea-
surement and reference material issues and therefore focused their
FIGURE 1. Crossover study (n = 280) comparing serum vitamin B-12
(B12) results using 2 different measurement procedures. A: Scatter plot with
Deming regression ﬁt of log-transformed vitamin B-12 concentrations as
measured by the Roche E-170 procedure (Roche, Basel, Switzerland). com-
pared with the Bio-Rad Quantaphase II radioimmunoassay (Bio-Rad Labo-
ratories, Hercules, CA). The Deming equation was: log B12Roche = 0.97 ·
log B12Bio-Rad + 0.10 pmol/L. The SE was 0.012 for the slope and 0.025 for
the intercept. B: Bland-Altman difference plot of vitamin B-12 concentra-
tions between the Roche E-170 procedure and the Bio-Rad Quantaphase II
radioimmunoassay. Each data point represents the relative difference be-
tween the 2 assays as a function of the mean between the 2 assays. The
mean relative bias for the Roche procedure compared with the Bio-Rad
procedure was 10.7%, and the 95% limits of agreement were from 25.6%
to 27%.
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markers in future NHANES.
Reinstatement of vitamin B-12 biomarkers in NHANES
Overall, the roundtable experts supported reinstating vitamin
B-12–related biomarker measurement in future NHANES and
discussed possible reasons to justify its inclusion in future
NHANES. The roundtable noted that interest in monitoring vi-
tamin B-12 status began with folic acid fortiﬁcation of cereal
grains in the United States in 1996, because this fortiﬁcation
might mask hematologic symptoms of vitamin B-12 deﬁciency,
resulting in diagnosis and treatment delays that would promote
the progression of mild vitamin B-12 insufﬁciency to more clin-
ically severe deﬁciency. However, before and after fortiﬁcation,
median serum vitamin B-12 concentrations (343–356 pmol/L) and
the prevalenceof serum vitamin B-12 concentrations ,148 pmol/L
(2.7–4.8%) did not change appreciably (29). Only 2% of the US
population had high MMA concentrations indicating inadequate
vitamin B-12 status (.370 nmol/L) in NHANES 1999–2000,
although prevalence in persons aged 60 y was 7% (56).
The roundtable noted that the lack of change in serum vitamin
B-12concentrationsmaybemisleadingbecauseofthelonglatency
periodrequiredtodevelopvitaminB-12deﬁciency.Alternatively,
the assumption that mild vitamin B-12 deﬁciencyis verylikely to
progress to more severe clinical deﬁciency may be erroneous (9).
Some roundtable experts noted that the ratio of high folate con-
centrationstolowvitaminB-12statusgeneratedthemostconcern
about potential adverse effects of folic acid fortiﬁcation. Selhub
et al (15) observed anemia and cognitive impairment ’5 times
more often in the group with elevated folate status (.59 nmol/L)
incombinationwithlowvitaminB-12status(serum,148pmol/L
or MMA .210 nmol/L) than in the group with normal vitamin
B-12 and folate status.
The roundtable noted that the evolving observational evidence
that suggests an association between subclinical vitamin B-12
deﬁciencies and adverse effects is of concern. However, pending
theavailabilityofclinicaltrialstoconﬁrmacausalrelationbetween
mild vitamin B-12 deﬁciency and adverse effects, whether mild
vitamin B-12 deﬁciencyimposes a public health risk is uncertain.
Beginning in 2011, NHANES will include 3 cognitive function
measures. Several experts thought that these new data would be
useful to explore previously observed associations with the more
limitedcognitivefunctiondatainpastNHANES.However,others
questioned the relevance to vitamin B-12 deﬁciency of cognitive
function tests designed to detect Alzheimer disease or the con-
tinued need for more NHANES hypothesis-generating research,
given that several observational studies have already identiﬁed
associations between vitamin B-12 status and cognitive function.
AnotherreasontoreinstatevitaminB-12biomarkermeasuresisthe
need for population-based prevalence estimates as new data be-
come available from clinical trials. NHANES data could also
provide useful information on the quantitative relation between
intakes and biomarker concentrations, although malabsorption
problems with some vitamin B-12 insufﬁciencies would compli-
catesuchanalyses.Someexpertssuggestedestimatingabsorption
status by a blood test (eg, intrinsic factor antibody) in peoplewith
low vitamin B-12 status to distinguish patients with pernicious
anemiafromthosewithlowvitaminB-12statusduetoothercauses.
The roundtable considered population-based changes beyond
the aging US population that could affect vitamin B-12 status and
would justify including vitamin B-12 biomarkers in future
NHANES. More people use proton pump inhibitors and hista-
mine 2 receptor antagonists (H2 blockers) that may decrease
vitamin B-12 absorption; these are now available over-the-counter
(57, 58). Other changes, such as the common use of antibiotics in
TABLE 2
Methylmalonic acid measurements in NHANES
1
Survey Measurement procedure Matrix Laboratory Population age
1974–1975 — — — —
1976–1980 — — — —
1988–1994 GC/MS Surplus serum Tufts University 30–39 y, 65 y
1999–2000 GC/MS Plasma NCEH 3y
2001–2002 GC/MS Plasma NCEH 3y
2003–2004 GC/MS Plasma NCEH 3y
2005–2006 — — — —
2007–2008 — — — —
2009–2010 — — — —
1 GC/MS, gas chromatography/mass spectrometry; Tufts University, Jean Mayer US Department of Agriculture
Human Nutrition Research Center on Aging, Boston, MA; NCEH, National Center for Environmental Health, Centers
for Disease Control and Prevention.
TABLE 3
Total homocysteine measurements in NHANES
1
Survey
Measurement
procedure Matrix Laboratory
Population
age
1974–1975 — — — —
1976–1980 — — — —
1988–1991 — — — —
1991–1994 HPLC-FD Surplus serum Tufts 12 y
1999–2000 Abbott FPIA IMx Plasma NCEH 3y
2001 Abbott FPIA IMx Plasma NCEH 3y
2002 Abbot FPIA AxSYM Plasma NCEH 3y
2003–2004 Abbott FPIA AxSYM Plasma NCEH 3y
2005–2006 Abbott FPIA AxSYM Plasma NCEH 20 y
2007–2008 — — — —
2009–2010 — — — —
1 HPLC-FD, HPLC with ﬂuorescence detection; FPIA, ﬂuorescence po-
larization immunoassay (AxSYM and IMx; Abbott Diagnostics, Abbott Park,
IL); NCEH, National Center for Environmental Health, Centers for Disease
Control and Prevention; Tufts, Tufts University, Jean Mayer US Department of
Agriculture Human Nutrition Research Center on Aging, Boston, MA.
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tamin B-12 status by decreasing Helicobacter pylori infections
that have statistical associations with decreased vitamin B-12
absorption. Increased adoption of vegan diets, the substitution of
chicken for beef, and decreased use of dairy products could
lower vitamin B-12 intakes. Several experts felt that as the use of
vitamin B-12–containing supplements (including some with doses
of 1000–2000 lg/d) and fortiﬁed foods increases, monitoring long-
term, high vitamin B-12 intakes would be useful to evaluate the
safety of chronic exposures to excessively high intakes in healthy
populations. Monitoring vitamin B-12 intakes could help assess
whether lifestyle changes are associated with changes in vita-
min B-12 status.
Which biomarkers should future NHANES include?
The roundtable addressed which biomarkers to include in
NHANES if the program reinstates vitamin B-12 status moni-
toring. Given each biomarker’s sensitivity and speciﬁcity prob-
lems, the results of a single biomarker measurement would be
difﬁcult to interpret. But if NHANES can measure only one
biomarker, some experts felt that this measure should reﬂect the
broad range of vitamin B-12 status in the US population. Vitamin
B-12 and holoTC increase continuously with increasing intakes,
at least until vitamin B-12 saturates the transport proteins, and
therefore reﬂect a broad range of intakes and status. Other ro-
undtable experts felt that the sensitivity of MMA and tHcy to
early inadequacies in vitamin B-12 status and marginal vitamin
B-12 intakes could support the use of either one as the sole
NHANES biomarker. Mean corpuscular volume to detect meg-
aloblastic anemia would not be useful because ,10% of patients
with vitamin B-12 deﬁciency have megaloblastic anemia, and
high mean corpuscular volume is more likely to reﬂect alcohol
abuse than vitamin B-12 deﬁciency (9).
However, the roundtable strongly urged that, given the sen-
sitivity and speciﬁcity problems of all vitamin B-12–related
biomarkers, future NHANES should concurrently measure at
least onebiomarker ofcirculating concentrations ofvitaminB-12
(vitamin B-12 or holoTC) and one biomarker of functional vi-
tamin B-12 status (MMA or tHcy). If a choice must be made
between serum vitamin B-12 and holoTC, holoTC has the ad-
vantage of not being affected by “false-positive” low vitamin B-12
concentrations such as those caused by genetically determined
haptocorrin deﬁciencies. These conditions result in low circu-
lating vitamin B-12 concentrations but have no adverse effect on
vitamin B-12 status because they do not affect holoTC, which
is the universal transport protein for vitamin B-12 uptake in all
cells. However, the roundtable also recognized that holoTC mea-
surement is new and would beneﬁt from additional performance
studies to engender full conﬁdence in the use of holoTC for
population-based surveys. Therefore, at this time, the roundtable
agreed that serum vitamin B-12 is preferable over holoTC as the
measure of circulating concentrations of vitamin B-12. MMA is
preferable to tHcy if a choice must be made between these bio-
markersbecauseitincreaseswithvitaminB-12inadequacy,butnot
with folate inadequacy, whereas both of these nutrient deﬁciencies
affect tHcy.
The roundtable generally agreed that, if NHANES reinstates
2 vitamin B-12–related biomarkers, serum vitamin B-12 and
plasma MMA would provide continuity with past surveys and
provide circulating and functional indicators of vitamin B-12
status. These variables have shown associations with anemia and
cognitivedeclineinpreviousNHANESandinotherstudies(12–15,
59). Reliable measurement procedures are available, and the NIST
is developing reference materials. The roundtable also suggested
that NHANES periodically measure vitamin B-12, holoTC, MMA,
and tHcy concurrently to provide valuable information on their
relations in the general population and on how prevalence estimates
vary by biomarker or biomarker combinations.
SUMMARY
In July 2010, a roundtable reviewed the measurement of vi-
tamin B-12 status biomarkers in NHANES. The roundtable was
uncertain whether subclinical vitamin B-12 deﬁciency is a public
health problem warranting population-based monitoring. How-
ever, associations between subclinical vitamin B-12 deﬁciency
and adverse healthoutcomesinobservational studiesareof concern
and urgently need further evaluation in clinical trials. Clinical trials
must use accurate and reliable measurement procedures to de-
termine appropriatecutoffs for biomarker concentrations toidentify
at-risk populations. The roundtable was generally satisﬁed with the
vitaminB-12biomarkermeasurementproceduresthatpastNHANES
have used or that are available for use in future NHANES, as well
as the reference methods and materials available from, or under
development by, the NIST. The experts supported reinstating
vitamin B-12–related biomarkers in future NHANES and sug-
gested several public health and environmental reasons for doing
so. Finally, the roundtable agreed that future NHANES should
include at least 2 biomarkers—1 of circulating vitamin B-12
concentrations(preferablyvitaminB-12)and1metabolicindicator
of vitamin B-12 insufﬁciency (preferably MMA).
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